Providing independent clinical excellence since 2005
A 2026 BMJ systematic review confirms that weight regain is the rule after stopping pharmacological weight-management therapy. Across drug classes, most lost weight is regained within 24 months, with parallel loss of metabolic benefit. This reflects biological defence of adiposity, not patient failure.
The most effective path to reducing visceral fat with the help of GLP-1 mimetic is not just to “eat less.” It’s to build more muscle, eat smarter, and track your progress. In this blog, which also forms one of the chapters of an ebook, I outline the programme and tools our patients use in our cardiometabolic clinic.
GLP-1 drugs seem paradoxical: they enhance insulin action yet shrink dangerous belly fat. The explanation lies in restoring normal insulin timing, reducing chronic insulin exposure, and reversing fat “spillover” from liver to abdomen. Real patient cases show rapid visceral fat loss alongside smoother glucose profiles and lower cardiovascular risk.
Semaglutide’s cardiovascular benefits extend beyond weight loss — it powerfully reduces visceral adipose tissue (VAT), the internal fat that drives inflammation, insulin resistance and small dense LDL. At SCVC, our GLP-1 programme targets VAT directly using personalised VAT scans and flexible dosing to improve long-term heart health.
If you’re taking GLP-1 mimetics like Mounjaro, Ozempic, or Wegovy, you’re receiving a legitimate, medically prescribed therapy. Just like someone with asthma carries an inhaler, or a diabetic uses insulin, there’s no shame in needing a jab to support your metabolic health. Whether you are travelling or attending a hospitality event, here are some tips on how to navigate these new waters.